行情

ZGNX

ZGNX

Zogenix
NASDAQ

实时行情|Nasdaq Last Sale

45.69
+0.70
+1.54%
已收盘, 16:11 11/19 EST
开盘
45.20
昨收
45.00
最高
46.54
最低
44.92
成交量
48.37万
成交额
--
52周最高
56.50
52周最低
33.43
市值
20.22亿
市盈率(TTM)
-5.0729
分时
5日
1月
3月
1年
5年

分析师评级

13位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ZGNX 新闻

  • 沪指低开低走 纽约联储主席称美经济面临下行风险
  • 新浪财经.1小时前
  • 不止做手机 苹果新专利涉及自动驾驶
  • 快科技.7小时前
  • 波音737 MAX打破5个月僵局:在迪拜收获60架订单
  • 澎湃新闻.7小时前
  • 索尼IT人才年收入将超过1100万日元 比过去增加4成
  • 新浪财经综合.7小时前

更多

所属板块

生物技术和医学研究
+2.16%
制药与医学研究
+0.78%

热门股票

名称
价格
涨跌幅

ZGNX 简况

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.
展开

Webull提供Zogenix, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。